Anteris Technologies Global Corp.
AVR.ASXMarket Data
$12.270
+0.0%$1.2B
-100000.0x
$-99999.990
0.00%
+0.3%
Latest Earnings
2025 Financial Results and Corporate Update
27 February 2026
Anteris Technologies reported its FY2025 financial results, reflecting a pre-revenue clinical-stage company with net operating cash outflows of US$77.8 million driven by R&D spend of US$69.1 million and SG&A of US$26.1 million as it advances its DurAVR® THV through the global pivotal PARADIGM Trial. No revenue was reported, consistent with the company's development-stage status. Post-period, Anteris completed US$320 million in capital raises in early 2026, including a strategic investment from Medtronic, providing a significant funding runway to support commercialisation. Key points: Initiated the global pivotal PARADIGM Trial (~1,000 patients, head-to-head vs. commercial TAVRs), with first patients enrolled and implanted in Q4 2025.; Received FDA Investigational Device Exemption (IDE) approval in Q4 2025, enabling US enrolment in the PARADIGM Trial.; Treated 130 patients with DurAVR® THV to date, with favourable 30-day (100 patients) and 1-year (65 patients) clinical outcomes reported.
Recent Announcements
2025 Financial Results and Corporate Update
Anteris Technologies reported its FY2025 financial results, reflecting a pre-revenue clinical-stage company with net operating cash outflows of US$77.8 million driven by R&D spend of US$69.1 million and SG&A of US$26.1 million as it advances its DurAVR® THV through the global pivotal PARADIGM Trial. No revenue was reported, consistent with the company's development-stage status. Post-period, Anteris completed US$320 million in capital raises in early 2026, including a strategic investment from Medtronic, providing a significant funding runway to support commercialisation. Key points: Initiated the global pivotal PARADIGM Trial (~1,000 patients, head-to-head vs. commercial TAVRs), with first patients enrolled and implanted in Q4 2025.; Received FDA Investigational Device Exemption (IDE) approval in Q4 2025, enabling US enrolment in the PARADIGM Trial.; Treated 130 patients with DurAVR® THV to date, with favourable 30-day (100 patients) and 1-year (65 patients) clinical outcomes reported.
Get real-time alerts for AVR
Receive AI-powered earnings summaries and instant notifications when Anteris Technologies Global Corp. releases results.
Register Free